Session

Saturday
November 28
14:15 - 15:30
Online
Hypoxia-activated prodrugs: is there a future?
Hypoxia-activated prodrugs (HAPs) are antineoplastic agents selectively targeting hypoxic tumor regions associated with malignancy and treatment resistance. Ahmed Salem will give an overview of the HAP clinical trials with the likely reasons for their disappointing results and explain how to design a successful hypoxia biomarker-guided trial. Alexandra Mowday will discuss how possible HAP off-target activity can be exploited, removed or re-purposed and what the implications are on HAP activity at intermediate oxygen concentrations. Brad Wouters will elaborate on novel hypoxia-activated small molecules targeting unexpected biological pathways, while Martin Pruschy will discuss the do’s and don’ts of HAP combination therapies.
1320
Symposium
Radiobiology
15:05 - 15:30